Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed this Form 8-K on November 12, 2024, to report a significant corporate governance event regarding its listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The report focuses exclusively on regulatory compliance status.
Material Changes
The Company received a Compliance Notice from Nasdaq confirming it has regained compliance with Listing Rule 5450(a)(1), which mandates a minimum bid price of $1.00 per share. Previously, on June 20, 2024, the Company was notified of non-compliance due to its stock price falling below this threshold for 34 consecutive trading days. The Company successfully maintained a closing bid price of at least $1.00 per share for 10 consecutive business days between October 29, 2024, and November 11, 2024.
Outlook and Risks
Nasdaq has confirmed that the matter regarding the Minimum Bid Price Requirement is now closed. No new risks, contingencies, or forward-looking guidance were disclosed in this specific filing.
Investor Verification Checklist
- Verify the current trading price of QNCX to ensure it remains above the $1.00 threshold.
- Review the June 20, 2024, Nasdaq deficiency notice to understand the prior non-compliance period.
- Confirm that no further action is required by the Company to maintain listing status under Rule 5450(a)(1).